Omeros Corporation 0KBU.L Stock
Omeros Corporation Price Chart
Omeros Corporation 0KBU.L Financial and Trading Overview
Omeros Corporation stock price | 3.95 USD |
Previous Close | 6.26 USD |
Open | 0 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 7.78 USD |
Volume | 3.8K USD |
Avg. Volume | 3.1K USD |
Market Cap | 2.66M USD |
Beta (5Y Monthly) | 1.067253 |
PE Ratio (TTM) | 0.019353297 |
EPS (TTM) | 3.14 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0KBU.L Valuation Measures
Enterprise Value | 489.66M USD |
Trailing P/E | 0.019353297 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 6.9508004 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -3 |
Trading Information
Omeros Corporation Stock Price History
Beta (5Y Monthly) | 1.067253 |
52-Week Change | 196.52% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.78 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 5.81 USD |
200-Day Moving Average | 4.28 USD |
0KBU.L Share Statistics
Avg. Volume (3 month) | 3.1K USD |
Avg. Daily Volume (10-Days) | 2.58K USD |
Shares Outstanding | 49.01M |
Float | 60.3M |
Short Ratio | N/A |
% Held by Insiders | 4.02% |
% Held by Institutions | 32.40% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -22.065% |
Return on Equity (ttm) | -728.71% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -163196000 USD |
Net Income Avi to Common (ttm) | -182218000 USD |
Diluted EPS (ttm) | 3.139 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 371.36M USD |
Total Cash Per Share (mrq) | 5.91 USD |
Total Debt (mrq) | 467.48M USD |
Total Debt/Equity (mrq) | 850.95 USD |
Current Ratio (mrq) | 2.996 |
Book Value Per Share (mrq) | 0.874 |
Cash Flow Statement
Operating Cash Flow (ttm) | 103.25M USD |
Levered Free Cash Flow (ttm) | -76187752 USD |
Profile of Omeros Corporation
Country | United Kingdom |
State | WA |
City | Seattle |
Address | The Omeros Building |
ZIP | 98119 |
Phone | 206 676 5000 |
Website | https://www.omeros.com |
Industry | |
Sector(s) | |
Full Time Employees | 196 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Q&A For Omeros Corporation Stock
What is a current 0KBU.L stock price?
Omeros Corporation 0KBU.L stock price today per share is 3.95 USD.
How to purchase Omeros Corporation stock?
You can buy 0KBU.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Omeros Corporation?
The stock symbol or ticker of Omeros Corporation is 0KBU.L.
How many shares does Omeros Corporation have in circulation?
The max supply of Omeros Corporation shares is 437.81K.
What is Omeros Corporation Price to Earnings Ratio (PE Ratio)?
Omeros Corporation PE Ratio is 0.01257566 now.
What was Omeros Corporation earnings per share over the trailing 12 months (TTM)?
Omeros Corporation EPS is 3.14 USD over the trailing 12 months.